Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
Ask The Pharmacist: Buprenorphine’s Role in Workers’ Compensation Pain Management
Buprenorphine, a Schedule III controlled substance approved by the U.S. Food and Drug Administration (FDA), is increasingly being considered for pain management in workers' compensation cases. This partial opioid agonist offers a unique profile that balances effective pain relief with a lower risk of abuse and dependence compared to full opioid agonists.
Overcoming Overpayment Risk With FairPay Flex
Enhance your specialty bill review workflow with Enlyte's FairPay Flex. Learn how our dedicated team can resolve disputes and streamline processes.
Collision Claims Increased by More Than 30% While Average Severity Plateaued for Battery Electric Vehicles Last Year
Mitchell today announced the latest release of its Plugged-In: EV Collision Insights report. This edition features an overview of the most notable annual trends in battery electric vehicle (BEV), mild hybrid electric vehicle (MHEV) and plug-in hybrid electric vehicle (PHEV) collision claims. Following a second year of record sales for new cars with electrified powertrains, claims frequency for repairable BEVs rose to 2.71% in the U.S. and 3.84% in Canada in 2024, a year-over-year increase of 38% and 34% respectively.
Plugged-In: EV Collision Insights 2024 Year in Review
Claims frequency for collision-damaged, repairable battery electric vehicles (BEVs) rose to 2.71% in the U.S. and 3.84% in Canada in 2024, a year-over-year increase of 38% and 34% respectively. CNBC reported that BEVs and hybrids represented 20% of all new U.S. vehicle sales in 2024, and Cox Automotive is predicting that number to climb to 25% in 2025 despite U.S. policy changes that could hinder BEV adoption.
A Guide to Making Specialty Bill Review a Good Fit for You: An Account Manager's Perspective
In the complex world of medical bill review, specialty bill review stands out as a powerful tool for achieving significant savings. Chad Countryman, a seasoned account success director at Enlyte, shares his insights on how he coaches clients to understand and implement FairPay Flex effectively.
CSN Collision Conference 2025
The 2025 CSN Collision Conference is an engaging and informative gathering for industry professionals.